Scarica l'app Stockscreener
40.90
4.37%
-1.87
Dopo l'orario di chiusura:
41.38
0.48
+1.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Precedente Chiudi:
$42.77
Aprire:
$43
Volume 24 ore:
556.15K
Relative Volume:
0.77
Capitalizzazione di mercato:
$3.06B
Reddito:
$35.93M
Utile/perdita netta:
$-244.56M
Rapporto P/E:
-10.35
EPS:
-3.95
Flusso di cassa netto:
$-157.31M
1 W Prestazione:
-7.45%
1M Prestazione:
+3.39%
6M Prestazione:
-24.95%
1 anno Prestazione:
-9.35%
Intervallo 1D:
$40.90
$44.22
Intervallo di 1 settimana:
$37.92
$45.12
Portata 52W:
$33.19
$61.61
Merus N V Stock (MRUS) Company Profile
Nome
Merus N V
Settore
Industria
Telefono
31 030 253 8800
Indirizzo
YALELAAN 62, 3584 CM UTRECHT
Confronta MRUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
40.90 | 3.06B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-02-07 | Iniziato | Wells Fargo | Overweight |
| 2024-11-21 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-03-28 | Iniziato | Truist | Buy |
| 2024-03-04 | Reiterato | Needham | Buy |
| 2023-11-02 | Iniziato | Canaccord Genuity | Buy |
| 2023-08-21 | Iniziato | TD Cowen | Outperform |
| 2022-08-02 | Iniziato | Stifel | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Needham | Buy |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-06-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-08 | Iniziato | William Blair | Outperform |
| 2021-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Ripresa | Guggenheim | Buy |
| 2019-06-28 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Ripresa | Guggenheim | Buy |
| 2019-04-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-03-21 | Downgrade | Citigroup | Buy → Neutral |
| 2016-12-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2016-06-13 | Iniziato | Citigroup | Buy |
| 2016-06-13 | Iniziato | Guggenheim | Buy |
| 2016-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Merus N V Borsa (MRUS) Ultime notizie
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.
Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline - MSN
Wells Fargo Maintains Overweight Rating on MRUS but Lowers Price Target | MRUS Stock News - GuruFocus
Merus to Present at BofA Securities 2025 Health Care Conference - The Manila Times
Wells Fargo Adjusts Price Target for Merus (MRUS), Maintains Overweight Rating | MRUS Stock News - GuruFocus
Merus NV reports results for the quarter ended March 31Earnings Summary - TradingView
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (MRUS) Merus NV Posts Q1 Revenue $26.5M - marketscreener.com
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewswire
Financial Health Check: Examining Merus N.V (MRUS)’s Key Ratios - DWinneX
(MRUS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Was Merus N.V (MRUS)’s session last reading good? - uspostnews.com
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Q1 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
FY2027 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus (NASDAQ:MRUS) Position Lifted by Geode Capital Management LLC - Defense World
William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS) - Defense World
Market Watch Highlights: Merus N.V (MRUS) Ends on an Upturn Note at 45.28 - DWinneX
Russell Investments Group Ltd. Decreases Stock Holdings in Merus (NASDAQ:MRUS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Merus N.V (MRUS) Is Worth Accumulating At Current Levels - Stocksregister
Daily Progress: Merus N.V (MRUS) Drop -3.19, Closing at 41.83 - DWinneX
MRUS Stock Sees Decline of Approximately -3.22% in Last Five Days - knoxdaily.com
Merus N.V’s Banking’s 100-Day Moving Average at 43.17: Will the Stock Break Through? - investchronicle.com
A stock that deserves closer examination: Merus N.V (MRUS) - uspostnews.com
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - The Manila Times
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting | MRUS Stock News - GuruFocus
Merus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual Meeting - Nasdaq
Breakthrough Cancer Drug Outperforms Standard Treatment: Phase 2 Trial Shows Superior Survival Rates - Stock Titan
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals | Libero Quotidiano.it - Libero Quotidiano
Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Merus N.V (NASDAQ: MRUS): Getting A Free Pass? - stocksregister.com
Merus’ (MRUS) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Raymond James Financial Inc. Invests $347,000 in Merus (NASDAQ:MRUS) - Defense World
Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) - Seeking Alpha
KLP Kapitalforvaltning AS Purchases New Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus stock touches 52-week low at $37.76 amid market challenges By Investing.com - Investing.com South Africa
Merus stock touches 52-week low at $37.76 amid market challenges - Investing.com Australia
HighTower Advisors LLC Has $337,000 Position in Merus (NASDAQ:MRUS) - Defense World
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
How To Trade (MRUS) - news.stocktradersdaily.com
Leading Biotech Merus Showcases Next-Gen Antibody Technologies at Major Healthcare Conference - Stock Titan
Merus (NASDAQ:MRUS) Shares Purchased by Teacher Retirement System of Texas - Defense World
Merus N V Azioni (MRUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):